SBIO
Fund Stats as of 06/22/2017
Symbol SBIO
CUSIP 00162Q 593
ISIN US00162Q5936
Inception Date 12/30/2014
Dividends Paid Annual
Fund Type Exchange Traded Fund
Market Price $28.10
Last Trade Price $28.13
NAV $28.10
NAV Change $0.14
Total Net Assets $115,199,531
Total Market Value $115,213,008
Premium/Discount(%) 0.00%
Difference ($) $0.00
Volume 49,830
Shares Outstanding 4,100,000
Expenses as of 03/31/2016
Management Fee0.50%
Other Expenses0.00%
Total Operating Expenses0.50%
Fund Resources
Summary Prospectus 
Statement of Additional Information 
Quarterly Fact Sheet 
Quarterly Scorecard 
Statutory Prospectus 
Resource Library  

Daily Fund Holdings 94 total, as of 06/22/2017, subject to change

SecuritySymbolWeight
Exelixis Inc.EXEL5.09%
Kite Pharma Inc.KITE4.17%
Bluebird Bio Inc.BLUE3.80%
Taro Pharmaceutical Industries Ltd.TARO3.67%
Akorn Inc.AKRX3.27%
Galapagos NV Sponsored ADRGLPG3.13%
OPKO Health Inc.OPK2.93%
ACADIA Pharmaceuticals Inc.ACAD2.74%
Intercept Pharmaceuticals Inc.ICPT2.56%
Sage Therapeutics Inc.SAGE2.49%
Nektar TherapeuticsNKTR2.37%
Ultragenyx Pharmaceutical Inc.RARE2.18%
Agios Pharmaceuticals Inc.AGIO2.17%
Ironwood Pharmaceuticals Inc.IRWD2.06%
GW Pharmaceuticals PLCGWPH2.04%
Endo International PLCENDP2.04%
Ligand Pharmaceuticals Inc.LGND2.02%
Axovant Sciences Ltd.AXON1.99%
Theravance Biopharma Inc.TBPH1.78%
FibroGen Inc.FGEN1.77%
Supernus Pharmaceuticals Inc.SUPN1.72%
Portola Pharmaceuticals Inc.PTLA1.71%
Halozyme Therapeutics Inc.HALO1.62%
Loxo Oncology Inc.LOXO1.61%
Aerie Pharmaceuticals Inc.AERI1.53%
Spark Therapeutics Inc.ONCE1.53%
Horizon Pharma PLCHZNP1.51%
Pacira Pharmaceuticals Inc.PCRX1.50%
BeiGene Ltd.BGNE1.39%
Advanced Accelerator Applications SAAAAP1.37%
DBV Technologies SA Sponsored ADRDBVT1.35%
Array BioPharma Inc.ARRY1.17%
Emergent BioSolutions Inc.EBS1.09%
Acceleron Pharma Inc.XLRN1.03%
Global Blood Therapeutics Inc.GBT1.00%
Impax Laboratories Inc.IPXL0.95%
Aimmune Therapeutics Inc.AIMT0.78%
Forward Pharma ASFWP0.78%
Achaogen Inc.AKAO0.72%
Five Prime Therapeutics Inc.FPRX0.71%
Acorda Therapeutics Inc.ACOR0.68%
Biohaven Pharmaceutical Holding Co. Ltd.BHVN0.68%
Revance Therapeutics Inc.RVNC0.63%
Epizyme Inc.EPZM0.62%
Aduro Biotech Inc.ADRO0.61%
Ascendis Pharma AS ADRASND0.59%
Neuroderm Ltd.NDRM0.59%
Lannett Co. Inc.LCI0.58%
Enanta Pharmaceuticals Inc.ENTA0.55%
Depomed Inc.DEPO0.54%
Aclaris Therapeutics Inc.ACRS0.54%
Paratek Pharmaceuticals Inc.PRTK0.52%
MacroGenics Inc.MGNX0.51%
AMAG Pharmaceuticals Inc.AMAG0.50%
Flexion Therapeutics Inc.FLXN0.50%
Akebia Therapeutics Inc.AKBA0.50%
PTC Therapeutics Inc.PTCT0.48%
Versartis Inc.VSAR0.47%
Achillion Pharmaceuticals Inc.ACHN0.46%
NantKwest Inc.NK0.45%
SciClone Pharmaceuticals Inc.SCLN0.44%
Jounce Therapeutics Inc.JNCE0.43%
Progenics Pharmaceuticals Inc.PGNX0.42%
Otonomy Inc.OTIC0.42%
Ra Pharmaceuticals Inc.RARX0.41%
Aurinia Pharmaceuticals IncAUPH0.41%
G1 Therapeutics Inc.GTHX0.39%
Sucampo Pharmaceuticals Inc.SCMP0.39%
BioCryst Pharmaceuticals Inc.BCRX0.38%
AnaptysBio Inc.ANAB0.38%
Seres Therapeutics Inc.MCRB0.37%
Avadel Pharmaceuticals PLCAVDL0.35%
MyoKardia Inc.MYOK0.34%
Atara Biotherapeutics Inc.ATRA0.34%
Reata Pharmaceuticals Inc.RETA0.32%
PDL BioPharma Inc.PDLI0.31%
Adamas Pharmaceuticals Inc.ADMS0.29%
Adaptimmune Therapeutics PLCADAP0.27%
Minerva Neurosciences Inc.NERV0.27%
Aquinox Pharmaceuticals Inc.AQXP0.27%
Concert Pharmaceuticals Inc.CNCE0.26%
Ocular Therapeutix Inc.OCUL0.26%
Ovid therapeutics Inc.OVID0.24%
Tocagen Inc.TOCA0.23%
Corbus Pharmaceuticals Holdings Inc.CRBP0.23%
Syndax Pharmaceuticals Inc.SNDX0.23%
Idera Pharmaceuticals Inc.IDRA0.20%
Chimerix Inc.CMRX0.20%
Zynerba Pharmaceuticals Inc.ZYNE0.19%
Matinas BioPharma Holdings Inc.MTNB0.18%
UroGen Pharma Ltd.URGN0.17%
Dyax Corp. - CVRDYAX-CVR0.00%
State Street Institutional Treasury Plus Money Market FundTPIXX0.07%
Cash and Equivalents0.00%
Total Net Assets 100.00%
Security
Exelixis Inc.
Kite Pharma Inc.
Bluebird Bio Inc.
Taro Pharmaceutical Industries Ltd.
Akorn Inc.
Galapagos NV Sponsored ADR
OPKO Health Inc.
ACADIA Pharmaceuticals Inc.
Intercept Pharmaceuticals Inc.
Sage Therapeutics Inc.
Nektar Therapeutics
Ultragenyx Pharmaceutical Inc.
Agios Pharmaceuticals Inc.
Ironwood Pharmaceuticals Inc.
GW Pharmaceuticals PLC
Endo International PLC
Ligand Pharmaceuticals Inc.
Axovant Sciences Ltd.
Theravance Biopharma Inc.
FibroGen Inc.
Supernus Pharmaceuticals Inc.
Portola Pharmaceuticals Inc.
Halozyme Therapeutics Inc.
Loxo Oncology Inc.
Aerie Pharmaceuticals Inc.
Spark Therapeutics Inc.
Horizon Pharma PLC
Pacira Pharmaceuticals Inc.
BeiGene Ltd.
Advanced Accelerator Applications SA
DBV Technologies SA Sponsored ADR
Array BioPharma Inc.
Emergent BioSolutions Inc.
Acceleron Pharma Inc.
Global Blood Therapeutics Inc.
Impax Laboratories Inc.
Aimmune Therapeutics Inc.
Forward Pharma AS
Achaogen Inc.
Five Prime Therapeutics Inc.
Acorda Therapeutics Inc.
Biohaven Pharmaceutical Holding Co. Ltd.
Revance Therapeutics Inc.
Epizyme Inc.
Aduro Biotech Inc.
Ascendis Pharma AS ADR
Neuroderm Ltd.
Lannett Co. Inc.
Enanta Pharmaceuticals Inc.
Depomed Inc.
Aclaris Therapeutics Inc.
Paratek Pharmaceuticals Inc.
MacroGenics Inc.
AMAG Pharmaceuticals Inc.
Flexion Therapeutics Inc.
Akebia Therapeutics Inc.
PTC Therapeutics Inc.
Versartis Inc.
Achillion Pharmaceuticals Inc.
NantKwest Inc.
SciClone Pharmaceuticals Inc.
Jounce Therapeutics Inc.
Progenics Pharmaceuticals Inc.
Otonomy Inc.
Ra Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc
G1 Therapeutics Inc.
Sucampo Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc.
AnaptysBio Inc.
Seres Therapeutics Inc.
Avadel Pharmaceuticals PLC
MyoKardia Inc.
Atara Biotherapeutics Inc.
Reata Pharmaceuticals Inc.
PDL BioPharma Inc.
Adamas Pharmaceuticals Inc.
Adaptimmune Therapeutics PLC
Minerva Neurosciences Inc.
Aquinox Pharmaceuticals Inc.
Concert Pharmaceuticals Inc.
Ocular Therapeutix Inc.
Ovid therapeutics Inc.
Tocagen Inc.
Corbus Pharmaceuticals Holdings Inc.
Syndax Pharmaceuticals Inc.
Idera Pharmaceuticals Inc.
Chimerix Inc.
Zynerba Pharmaceuticals Inc.
Matinas BioPharma Holdings Inc.
UroGen Pharma Ltd.
Dyax Corp. - CVR
State Street Institutional Treasury Plus Money Market Fund
Cash and Equivalents
Total Net Assets